USIL THERAPEUTICS

USIL Therapeutics is a Luxembourg-based biotechnology company developing advanced medical countermeasures to protect people and critical infrastructure from the dangers of ionizing radiation. The company focuses on next-generation radioprotective solutions designed to safeguard military personnel, first responders, healthcare systems, and civilian populations in high-risk environments.

Driven by the mission to transform radiation defense, USIL Therapeutics is advancing breakthrough treatments that go beyond symptomatic care to provide whole-body protection before and after radiation exposure.

Its research portfolio includes patented molecules and dual-use medical solutions aimed at strengthening preparedness and resilience in the face of nuclear incidents, radiological emergencies, and high-risk industrial exposure.

Working in collaboration with governments, defence agencies, and strategic partners, the company supports global readiness and long-term security by delivering scalable radioprotection technologies for civilian and defence applications.

With expertise spanning radiobiology, pharmaceuticals, and large-scale deployment, USIL Therapeutics contributes to Europe’s health security and resilience agenda through innovation at the intersection of biotechnology, defence, and emergency preparedness.